No-react* anticalcification tissue treatment results with stentless heart valves in two adolescents  by Milo, Simcha et al.
Implantation of prosthetic heart valves in children is chal-
lenging. Calcification may lead to mechanical failure.1 The
No-React formula, (Shelhigh Inc, Millburn, NJ), a new tissue
preservation process applied to a wide range of bioprosthetic
products, involves treating the tissue with glutaraldehyde,
which is rinsed out, and then impregnating it with heparin and
surfactant. This process supposedly prevents mineral deposi-
tion within the implants.
The No-React process was shown to have anticalcification
properties in a subcutaneous implantation model of treated tis-
sues in rats.2 We therefore began in 1994 a clinical study at the
Rambam Medical Center in Haifa, Israel, on the use of No-
React products. We report here our experience with 2 children
in whom porcine BioCor heart valves (BioCor, Belohorizonte,
Brazil) treated with No-React were implanted.
Clinical summaries
PATIENT 1. A 13-year-old girl with a long history of
rheumatic heart disease and a recent history of suspected bac-
terial endocarditis was admitted to our institution on
December 10, 1994, with congestive heart failure. Echo-
cardiograms showed vegetations on and gross incompetence
of the mitral and aortic valves.
On December 27, 1994, we replaced the mitral and aortic
valves with 2 porcine stentless valves treated with No-React.
Results of blood and tissue culture were negative. The
patient’s clinical condition improved. Reduction in the size
of the left ventricle caused a slight prolapse of the anterior
mitral leaflet and a mild degree of mitral incompetence. She
was readmitted on May 14, 1997, with severe congestive
heart failure, atrial fibrillation, and severe mitral and aortic
regurgitation. We replaced both valves with mechanical bi-
leaflet prostheses. The explanted mitral valve, which was
calcified and immobile, had almost fixed leaflets and 1 of the
chordae tendineae was torn (Fig 1). The stentless aortic valve
had 1 torn cusp and mild calcification. The No-React peri-
cardial patch that had been used to enlarge the aortic root
was severely adherent on both sides to the surrounding struc-
tures. The patient was discharged on the ninth day after the
operation.
PATIENT 2. A 13-year-old boy with a history of rheumatic
heart disease was admitted to our hospital on May 23, 1995,
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Fig 1. Heavily calcified explanted stentless BioCor mitral bioprosthesis treated with No-React as viewed from
(A) left atrial side and (B) left ventricular side. Note thickening and rupture of chordae tendineae.
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with pulmonary edema resulting from severe mitral regurgita-
tion. Blood cultures grew Acinetobacter species. Aortic regur-
gitation and a ruptured posterior mitral leaflet without vegeta-
tions were seen on an echocardiogram. On May 30, 1995, we
replaced both valves with stentless BioCor porcine valves
treated with No-React. We saw no signs of bacterial endo-
carditis on the leaflets of either explanted valve. On June 2,
1997, an echocardiogram showed good valvular motion, min-
imal mitral regurgitation, no aortic regurgitation, and no mitral
stenosis. However, on August 6, 1997, he was readmitted with
pulmonary edema related to severe mitral regurgitation caused
by ruptured chordae tendineae of both mitral leaflets. On
August 10 we replaced the stentless mitral valve, which was
calcified and immobile with torn chordae tendineae and calci-
fied leaflets, with a mechanical bileaflet valve. The aortic
valve, which showed no signs of malfunction or calcification,
was left in place. He was discharged 10 days later.
Discussion. In our study the time from implantation to
explantation of the 2 stentless porcine mitral valves treat-
ed with No-React and the 1 stentless aortic valve ranged
between 26 and 29 months, similar to the duration report-
ed for glutaraldehyde-preserved bioprostheses used in
children.3
The finding of native valve endocarditis in both our
patients raises the question of whether implantation of any
bioprosthesis in an infected, inflamed area might enhance
biodegradation. We found that the explanted stentless mitral
valves were significantly more calcified and immobile than
were the aortic valves. In the first patient the torn cusp, which
indicates biodegradation,4 was the indication for replacement
rather than calcification. The uncalcified aortic valve in the
second patient was not replaced. Whether the difference in
the rate of calcification between the mitral and aortic No-
React bioprostheses is selective or dependent on design
remains unclear. The tissue overgrowth on the chordae
tendineae was similar to that seen in prosthetic chordal
replacement with polytetrafluoroethylene* or in other bio-
prostheses preserved in glutaraldehyde after failure. Both
sides of the No-React pericardial patch used to enlarge the
aortic root had massive adhesions.
We based our study on studies in the juvenile rat model.2
Because of our poor outcome we question the validity of the
rat model for predicting calcification in children. In a recent
comparative study Shen and associates5 reported that the rab-
bit subcutaneous model was a better predictor of clinical out-
come with respect to calcification than was the rat model.
Our findings raise questions regarding the anticalcification
properties of the No-React process, especially in adolescents.
We thank Rebecca Bartow, PhD, for editorial consultation and
our dedicated laboratory technician, Mr Alexander Chikovaney,
for preparing the explanted material for this publication.
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*Gore-Tex patch; Gore-Tex is a registered trademark of W. L. Gore
& Associates, Inc, Flagstaff, Ariz.
